Tabocine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tabocine

Quick Facts

Property Description
Active Ingredient Doxycycline
Form Capsules, Tablets, Oral Suspension, IV Solution
Pharmacological Class Tetracycline Antibiotic
Common Use Stopping bacterial infection progression
Origin Semi-synthetic

Tabocine is a medicinal product containing the active ingredient Doxycycline, which is primarily classified as a broad-spectrum antibiotic and a member of the Tetracycline class of medicines. This designation signifies the drug's role as a compound designed to impede the growth of various susceptible bacteria. Doxycycline is a cornerstone antibiotic, clinically recognized for its versatile application across systemic and soft-tissue infections.


Tabocine: Definition and Pharmacological Classification

Tabocine is identified by its active substance, Doxycycline, which is formally classified as a Tetracycline antibiotic. This pharmacological class is distinguished by its specific mode of action against bacterial life processes. The substance itself is a semi-synthetic derivative, a key factor developed to optimize properties like stability and absorption compared to first-generation agents. Doxycycline is recognized on the Model List of Essential Medicines, a high-level designation affirming that the drug is considered critical for addressing priority health needs globally.


Composition, Forms, and General Use

The core of Tabocine's composition is the single active substance, Doxycycline, typically present as salt forms such as Doxycycline monohydrate or Doxycycline hyclate. Tabocine is available in multiple dosage forms, including capsules, tablets, oral suspension, and sterile preparations for intravenous infusion, allowing its delivery via oral or intravenous routes. The general therapeutic purpose of this medicine stems from its function as a bacteriostatic agent: its principal action is to stop the growth and multiplication of susceptible bacteria, limiting the infection's progression and providing the patient's immune system the necessary opportunity to clear the residual pathogens.

Regulatory References

  1. World Health Organization

What side effects are possible with Tabocine?

Possible side effects and safety information

The safety profile for Tabocine (Doxycycline) is established by regulatory documentation, grouping possible effects into official classifications and system-organ classes.

Official Adverse Reaction Categories

Adverse reactions are formally classified by incidence. Reactions such as nausea, vomiting, diarrhea, and photosensitivity (an exaggerated sunburn reaction) are frequently reported and classified as Common. Less frequent events, such as abnormal hepatic function and jaundice, are listed as Rare in regulatory sources.

System-organ classes involved include Gastrointestinal Disorders (e.g., esophagitis, enterocolitis), Skin and Subcutaneous Tissue Disorders, Nervous System Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions and Safety Constraints

Clinically significant adverse reactions documented in official labels include Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which are severe dermatologic conditions. A serious neurological effect documented is Benign Intracranial Hypertension (Pseudotumor Cerebri), which carries a risk of visual impairment. The label also addresses the potential for superinfections due to the overgrowth of non-susceptible organisms, including fungi.

Specific safety restrictions apply to certain populations. The use of Tabocine is generally restricted during fetal tooth development (last half of pregnancy) and in children under 8 years of age due to the risk of permanent tooth discoloration (yellow-gray-brown) and inhibition of bone growth. The safety profile is also tied to exposure, with long-term use requiring consideration for possible laboratory monitoring.

Overdose and Emergency Response

The official regulatory documents define the overdose profile for Tabocine (Doxycycline) based on the risk of severe systemic effects resulting from excessive exposure. Documented presentations of an acute overdose typically involve an exaggeration of known adverse effects, most commonly manifesting as acute gastrointestinal symptoms, including significant nausea, vomiting, and diarrhea.

Immediate medical attention is required upon any suspicion or confirmation of an overdose. This action is mandated by regulatory agencies due to the potential for serious systemic outcomes, specifically the risk of hepatotoxicity (liver damage) and acute renal impairment (kidney function deterioration).

Management of the overdose is strictly symptomatic and supportive, as no specific antidote is known for Doxycycline. Where acute ingestion has occurred recently, procedural interventions such as gastric lavage or the administration of activated charcoal may be considered. Following stabilization, close clinical observation and laboratory monitoring of hepatic and renal function are mandated by official guidelines. Due to the drug’s properties, official labeling advises that methods like dialysis are generally ineffective for removing the medication from the bloodstream.

Therapeutic Uses of Tabocine

This medication is commonly used to address conditions presenting with systemic or localized discomfort across multiple therapeutic domains.

It is applied in clinical settings that involve acute or disruptive symptom patterns related to specific serious infections, including rickettsial diseases, Anthrax, Chlamydia, and Syphilis (as an alternative therapy). It also plays a role in managing symptoms related to inflammatory or irritative states in chronic skin disorders like severe acne and rosacea, and is relevant for Malaria prophylaxis.

Quick Fact: Relief for Inflammatory Symptoms

Category Description
Symptom Type Acute Systemic & Chronic Inflammatory
Context Management of Infectious Processes & Long-Term Management
Primary Benefit Contributes to easing the overall symptom load

In these situations, Tabocine supports the patient during difficult episodes by easing distress. It is applied in scenarios where additional management of discomfort is required to support symptomatic relief. This supportive relief may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview of Doxycycline

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Tabocine (Doxycycline) — Official Regulatory Information

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is contraindicated: Individuals with known hypersensitivity to any tetracycline-class antibiotic. Women who are pregnant (due to fetal risk of permanent dental discoloration and bone growth inhibition).
Populations for whom use is not recommended: Children under 8 years of age for routine use. Lactating women (breastfeeding is not recommended).
Age-related eligibility rules: Routine use is established for adults and children 8 years and older. Use in children under 8 is reserved only for severe or life-threatening conditions where alternatives are unavailable. Older adults require cautious dose selection due to potential organ function decline.
Condition-specific eligibility rules: Renal (Kidney) Impairment: No dose adjustment is required. Hepatic (Liver) Impairment: Use requires caution due to excretion routes.
Eligibility-related restrictions: Contraindication or avoidance of use is noted for patients with Myasthenia Gravis and for those concurrently taking Isotretinoin (due to risk of Intracranial Hypertension).

Eligibility Classifications (High-Level)

Category Classification Details
Eligibility severity classification: Officially classified as Contraindicated, Not Recommended, or permitted with Caution by regulatory authorities.
Eligibility-context constraints: Constraints relate to developmental risk (age, pregnancy), allergy, and risk of exacerbation in certain comorbid conditions.

Resulting Eligibility Structure

Official Eligibility Statements:

  • • Use is contraindicated in individuals with a known hypersensitivity to Doxycycline or other tetracyclines.
  • • Use is contraindicated during pregnancy, specifically due to the risk of permanent dental discoloration and bone growth inhibition in the fetus.
  • • The medicine is not recommended for children under 8 years of age, except for the treatment of severe, life-threatening infections where alternatives are deemed ineffective or unavailable.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents define who can and cannot use the medicine by establishing absolute contraindications based on hypersensitivity and fetal developmental risk, and by setting strict conditional limits for use in young children and patients with specific comorbid conditions like Myasthenia Gravis or hepatic impairment. This structure ensures that patient populations most vulnerable to the Tetracycline class's known risks are officially restricted or prohibited from receiving the medicine.

What should I know about interactions with other medicines?

This medication (commonly known as Doxycycline) has documented interactions with several categories of medicinal products, which may alter the effectiveness of either drug or increase the risk of serious side effects.

Products Not Recommended or Requiring Caution

Category Example Agents Interaction Concern
Oral Retinoids Isotretinoin, Acitretin Increased risk of intracranial hypertension (increased pressure around the brain). Concomitant use should be avoided.
Anticoagulants Warfarin May depress plasma prothrombin activity, requiring a downward adjustment of anticoagulant dosage to prevent bleeding.
Penicillin General Concurrent use should be avoided as this bacteriostatic drug may interfere with the bactericidal action of penicillin.
Enzyme Inducers Phenytoin, Carbamazepine, Barbiturates These agents can decrease the half-life of Doxycycline, potentially reducing its therapeutic efficacy.

Absorption Interference

Absorption of Doxycycline is significantly impaired by products containing aluminum, calcium, or magnesium (such as antacids), as well as iron-containing preparations and Bismuth subsalicylate. Taking these products too closely together reduces the amount of Doxycycline absorbed by the body. A dose separation of several hours is typically advised.

Additionally, Doxycycline may render oral hormonal contraceptives less effective, suggesting the need for alternative or supplemental birth control methods during treatment. Patients must inform their healthcare provider of all prescription and over-the-counter medicines, vitamins, and supplements being used.

Mechanism of Action

The mechanism of Tabocine (Doxycycline) operates through two distinct biological domains: the inhibition of bacterial growth and the modulation of host inflammatory processes.

Inhibition of Bacterial Protein Assembly (Bacteriostatic Effect)

The primary action targets the prokaryotic 30S ribosomal subunit, a central component of the bacterial protein synthesis apparatus. Tabocine binds reversibly to this subunit, physically blocking the access of aminoacyl-tRNA molecules and thereby halting the bacterial translation pathway. This molecular interference prevents the synthesis of proteins required for subsequent cellular processes, leading to the physiological consequence of bacteriostasis—the arrest of bacterial proliferation.

Modulation of Host Enzymes (Anti-Tissue Damage Mechanism)

A secondary, non-antibiotic mechanism involves the drug’s ability to suppress the activity of host Matrix Metalloproteinases (MMPs). These enzymes are naturally overexpressed during inflammation and contribute to the destructive breakdown of connective tissues. By reducing MMP activity, Tabocine engages mechanisms that modify the rate of tissue degradation, leading to the physiological consequence of a decrease in the host's pathological breakdown of connective tissues during inflammatory states.

Dosage and Administration Information

Tabocine (Doxycycline) administration is formally approved via oral (capsules, tablets, suspension) and intravenous (IV) injection/infusion routes. For most systemic uses, the regimen begins with a 200 mg initial loading dose on the first day, typically divided into 100 mg administered every 12 hours. This is followed by a 100 mg daily maintenance dose, taken as a single dose or divided, for the remainder of the course.

Oral administration requires key procedural steps to mitigate the risk of esophageal irritation. Patients take the dose with an adequate volume of fluid (water) and remain in an upright position for approximately 30 minutes after swallowing the dose. While many formulations can be taken with food to ease potential gastric irritation, certain delayed-release forms must be taken on an empty stomach.

Treatment duration is highly variable, ranging from short courses (7 to 10 days) for acute infections to prolonged regimens (up to 60 days) for specific prophylactic uses. Dosage in children 8 years of age and older weighing less than 45 kg is calculated based on body weight. A notable characteristic of the administration is that no routine dose adjustment is typically required for patients presenting with impaired kidney (renal) function. The specific instructions for preparation and administration (e.g., IV dilution or "do not crush" warnings for certain forms) must be strictly observed.

Recent Clinical Evidence

Tabocine: Recent Clinical Evidence


Evidence for Use in Managing Acute Bacterial Infections

Tabocine was studied for its application in conditions associated with acute or disruptive episodes caused by certain bacteria, including rickettsial diseases, Anthrax, and Chlamydia/Syphilis treatments. The evidence relies on historical clinical trials, studies comparing outcomes against other antibiotics, and consensus treatment guidelines. Research examined outcomes related to systemic or functional imbalance, such as symptom resolution and microbiological eradication. Findings describe rates of symptom resolution and microbiological clearance measured in the study cohorts. Comparative research against all of today's newer antibiotics for these specific acute indications is limited.


Evidence for Use in Preventing Bacterial STIs (Prophylaxis)

Research has explored the use of Tabocine in specific populations for prophylaxis of certain bacterial STIs. Studies monitored the incidence rates of new Chlamydia, Syphilis, and Gonorrhea diagnoses in high-risk adult cohorts. Findings described patterns related to lower incidence rates of Chlamydia and Syphilis infection in the studied groups compared to controls. However, research highlights mixed measurements concerning Gonorrhea incidence. Evidence is limited concerning this application in other groups, such as cisgender women and general populations.


Evidence for Use in Chronic Inflammatory Skin Conditions

Tabocine was studied for its use in managing symptoms related to inflammatory or irritative states in chronic skin conditions like severe acne and rosacea. This research is largely based on Randomized Controlled Trials (RCTs). Research examined outcomes related to inflammatory or irritative states, such as the change in the count of inflammatory lesions and overall disease severity scores. Findings describe patterns observed in the studies related to measured changes in inflammatory lesion counts over the course of the research period. Long-term effects are not fully established beyond the standard trial duration of 12 to 16 weeks.


What is Still Uncertain about Tabocine Research

The evidence landscape, while extensive, has key areas where certainty remains low or research is still needed. A consistent uncertainty involves the long-term ecological consequences and the potential impact on the human body's microbiome from extended use, which may contribute to antimicrobial resistance over time. Research highlights that comparative evidence is lacking in some areas, and the evidence quality varies across studies, not always relying on high-level RCT data.

Key Studies & References

  1. Doxycycline Uses (NIH MedlinePlus overview)

Frequently Asked Questions (FAQ)

Common questions about Tabocine (FAQ)


Q: What is the main reason doctors prescribe Tabocine?

A: Tabocine (Doxycycline) is an antibacterial prescription medicine. Official product information states it is approved to treat a variety of bacterial infections, including those causing pneumonia, certain sexually transmitted infections (STIs), and vector-borne illnesses like Lyme disease.


Q: Is Tabocine available over the counter, or is it prescription only?

A: According to regulatory classification, Tabocine's active ingredient, Doxycycline, is an antibacterial prescription medicine. It is not available for purchase over the counter (OTC) and requires a healthcare provider’s prescription.


Q: Does Tabocine interact with common pain relievers like ibuprofen?

A: Official summaries of drug interactions do not report a specific conflict between Doxycycline and Ibuprofen. Official guidance describes the importance of communicating all medicines, including OTC pain relievers, to a healthcare provider.


Q: Is it safe to drink coffee while using Tabocine?

A: Official guidance on Doxycycline does not specifically restrict coffee consumption. The concern involves absorption, as the drug can be significantly impaired by products containing high levels of minerals like calcium, iron, or magnesium. Official guidance suggests separating the dose by several hours from any products containing these mineral components to limit interference with absorption.


Q: Can Tabocine cause dizziness or drowsiness?

A: Adverse reactions listed in official documents include headache and may rarely include dizziness. A serious, though rare, neurological effect documented is Benign Intracranial Hypertension, which can cause headache and visual disturbances. Drowsiness is not commonly listed as a direct side effect.


Q: What happens if I miss a dose of Tabocine?

A: Official patient guidance describes what to do if a dose is missed. Generally, if a dose is missed, it may be taken as soon as you remember. If it is almost time for the next scheduled dose, the regulatory guidance suggests skipping the missed dose and continuing the regular schedule. Taking extra medicine to make up for a missed dose is not advised.


Q: How long does Tabocine stay in your system after stopping it?

A: Official pharmacokinetic information indicates that Tabocine (Doxycycline) has an elimination half-life typically ranging from about 18 to 23 hours in adults. A drug is generally considered cleared from the body after a period of approximately five half-lives.


Q: Is there a generic version of Tabocine available?

A: Yes, the active ingredient in Tabocine, Doxycycline, has been reviewed and approved by regulatory bodies to have multiple generic versions available on the market.


Q: What should I do if a side effect seems mild but doesn't go away?

A: Official patient counseling information recommends speaking to a healthcare provider or pharmacist if any side effects associated with the medicine trouble you, worsen, or do not go away. This guidance applies even to effects that are initially mild.


Q: Are the side effects of Tabocine different for men and women?

A: Official information notes that overweight females of childbearing age have a higher documented risk of developing Intracranial Hypertension, which is a serious neurological effect. Outside of this specific warning, the general list of common side effects does not typically differentiate between sexes in regulatory documents.


Q: Is Tabocine habit-forming or addictive?

A: According to official listings, Doxycycline is not classified as a controlled substance. Therefore, this medicine is not considered to be habit-forming or addictive.


Q: Does Tabocine affect your mood or mental state?

A: Adverse reactions are generally grouped under Nervous System Disorders in official documents. While some sources mention potential mental health impacts like anxiety or mood swings may occur, these are not listed as common side effects.


Q: Is it normal to feel a slight headache when starting Tabocine?

A: Headache is an officially listed adverse reaction and may occur when starting the medicine. However, headache is also a key symptom of the serious, though rare, neurological effect known as Intracranial Hypertension. Regulatory guidance suggests that persistent or severe symptoms are important to monitor.


Q: Does Tabocine interact with alcohol?

A: Official sources indicate that regular alcohol consumption can speed up the rate at which Doxycycline is cleared from the body. This can potentially reduce the medicine's effectiveness in treating an infection.


Q: Why is it important to know who cannot use Tabocine?

A: Warnings and contraindications are included in the regulatory label specifically to prevent serious harm. This includes preventing risks such as severe allergic reactions, permanent tooth discoloration in developing children and fetuses, and life-threatening conditions like Stevens-Johnson Syndrome.


Q: Does using Tabocine affect my ability to drive or operate machinery?

A: Official safety information notes that if side effects occur, such as dizziness or visual disturbances (a symptom of Intracranial Hypertension), caution is generally indicated when driving or operating machinery. Awareness of one's reaction to the medicine before undertaking these tasks is a general patient safety principle.


Q: Are there any known interactions between Tabocine and herbal supplements?

A: Official guidance describes the importance of informing a healthcare provider about all herbal products and supplements. Supplements containing minerals such as iron, calcium, magnesium, or zinc are known to bind with Doxycycline and reduce its absorption by the body.


Q: Can people with diabetes use Tabocine?

A: Official drug interaction data indicates that Doxycycline may interact with insulin or certain other diabetes medications. This potential interaction could increase the risk of low blood sugar, or hypoglycemia. Dose adjustments or more frequent monitoring of blood sugar may be important considerations.


Q: Does Tabocine need to be tapered off when stopping use?

A: Official patient information indicates that Doxycycline is generally safe to stop abruptly once the full prescribed course has been completed. It is important to ensure the medication is used exactly as directed to help prevent the recurrence of infection and antibiotic resistance.


Q: Are there any lifestyle changes recommended when using Tabocine?

A: Due to the risk of photosensitivity (an exaggerated sunburn reaction), official guidance strongly recommends specific measures to minimize sun exposure. This includes minimizing exposure to natural or artificial sunlight and utilizing protective measures like sunscreen (SPF 30+) and protective clothing while using the medicine.


Q: Why do some people report feeling tired when they first start Tabocine?

A: Regulatory documents do not list tiredness as a common, direct side effect. However, general adverse reactions like nausea, vomiting, or diarrhea can occur and indirectly contribute to feelings of tiredness or fatigue due to associated dehydration.


Q: Is there any public research available on the long-term effects of Tabocine?

A: Official regulatory documents acknowledge existing research on Doxycycline, but note that the long-term effects are not fully established beyond standard trial durations for some conditions. Uncertainty remains regarding the potential impact on the human body’s microbiome from extended use.


Q: Does Tabocine require any special monitoring while using it?

A: For patients with significantly impaired kidney function, monitoring of serum drug levels may be advisable if therapy is prolonged. Additionally, official regulatory sources state that long-term use for all patients requires consideration for possible laboratory monitoring.


Q: Is Tabocine generally well-tolerated according to studies?

A: Official documents list frequently reported and Common adverse reactions, such as nausea, vomiting, and diarrhea. The safety profile is well-established across various studies, but individual tolerability can vary based on the patient and the specific formulation used.


Q: What does official guidance say about taking Tabocine with or without food?

A: Official guidance states that most oral forms can be taken with food or milk to reduce gastric irritation. However, certain delayed-release forms must be taken on an empty stomach, and it is necessary to ensure all doses are taken with an adequate amount of fluid while remaining upright for 30 minutes.

How should Tabocine be stored and disposed of?

How to Store and Dispose of Tabocine (Doxycycline)

Official regulatory documents define strict conditions for the storage and disposal of Tabocine to maintain drug quality and ensure safety.

Storage Requirements

Tabocine (Doxycycline) must be stored at Controlled Room Temperature, which is specified as 20°C to 25°C. To protect its stability, the product must be protected from light and moisture and kept in a tightly closed container (oral forms) or its original container (IV solution). It is a mandatory regulatory requirement to keep Tabocine out of the sight and reach of children.

Disposal Instructions

Unused or expired Tabocine must not be thrown away via wastewater or standard household waste, as specified in regulatory labeling. Disposal must be performed according to local regulations, such as utilizing an authorized pharmaceutical drug take-back program or official collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tabocine found in:

A-Z Index: